Jennerex and Transgene have initiated patient enrolment and treatment for a Phase Ib clinical trial to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer.
The open-label, intravenous and multi-dose escalation study, which is being conducted at Samsung Cancer Center in Seoul, South Korea, is designed to evaluate the safety, tolerability and maximum tolerated dose of JX-594 for the treatment of refractory colorectal cancer.
The study will enrol up to 15 patients with metastatic colorectal cancer who have failed both oxaliplatin-based and irinotecan-based chemotherapy regimens, and whose tumour is refractory to Erbitux therapy or harbours ras mutations.
The patients will receive bi-weekly intravenous infusions of JX-594 at one of three dose levels.
JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData